Format

Send to

Choose Destination
Vaccine. 2017 Jun 22;35(29):3655-3660. doi: 10.1016/j.vaccine.2017.05.041. Epub 2017 May 25.

Maternal Tdap vaccination and risk of infant morbidity.

Author information

1
HealthPartners Institute, Minneapolis, United States. Electronic address: Malini.B.Desilva@healthpartners.com.
2
HealthPartners Institute, Minneapolis, United States.
3
Obstetrics and Gynecology, Yale University, New Haven, United States.
4
Kaiser Permanente Northern California, Oakland, United States.
5
Kaiser Permanente Southern California, Pasadena, United States.
6
Center for Health Research, Kaiser Permanente Northwest, Portland, United States.
7
Institute for Health Research, Kaiser Permanente Colorado and Department of Ambulatory Care Services, Denver Health, Denver, United States.
8
Harvard Pilgrim Health Care Institute & Lee Harvard Medical School, Boston, United States.
9
Group Health Cooperative, Seattle, United States.
10
Centers for Disease Control and Prevention, Atlanta, United States.

Abstract

INTRODUCTION:

An increased risk of diagnosed chorioamnionitis in women vaccinated with Tdap during pregnancy was previously detected at two Vaccine Safety Datalink (VSD) sites. The clinical significance of this finding related to infant outcomes remains uncertain.

METHODS:

Retrospective cohort study of singleton live births born to women who were continuously insured from 6months prior to their last menstrual period through 6weeks postpartum, with ≥1 outpatient visit during pregnancy from January 1, 2010 to November 15, 2013 at seven integrated United States health care systems part of the VSD. We re-evaluated the association between maternal Tdap and chorioamnionitis and evaluated whether specific infant morbidities differ among infants born to mothers who did and did not receive Tdap during pregnancy. We focused on 2 Tdap exposure windows: the recommended 27-36weeks gestation or anytime during pregnancy. We identified inpatient diagnostic codes for transient tachypnea of the newborn (TTN), neonatal sepsis, neonatal pneumonia, respiratory distress syndrome (RDS), and newborn convulsions associated with an infant's first hospitalization. A generalized linear model with Poisson distribution and log-link was used to estimate propensity score adjusted rate ratios (ARR) with 95% confidence intervals (CI).

RESULTS:

The analyses included 197,564 pregnancies. Chorioamnionitis was recorded in 6.4% of women who received Tdap vaccination any time during pregnancy and 5.2% of women who did not (ARR [95% CI]: 1.23 [1.17, 1.28]). Compared with unvaccinated women, there were no significant increased risks (ARR [95% CI]) for TTN (1.04 [0.98, 1.11]), neonatal sepsis (1.06 [0.91, 1.23]), neonatal pneumonia (0.94 [0.72, 1.22]), RDS (0.91 [0.66, 1.26]), or newborn convulsions (1.16 [0.87, 1.53]) in infants born to Tdap-vaccinated women.

CONCLUSIONS AND RELEVANCE:

Despite an observed association between maternal Tdap vaccination and maternal chorioamnionitis, we did not find increased risk for clinically significant infant outcomes associated with maternal chorioamnionitis.

KEYWORDS:

Chorioamnionitis; Infant; Vaccination

PMID:
28552511
DOI:
10.1016/j.vaccine.2017.05.041
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center